5Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology, 2006, 130: 935-939.
6Carter MJ, Lobo AJ, Travis Sp,et al. Guidelines for the management of inflammatory bowel disease in adults. Gut, 2004, 53 (Suppl 5) :Ⅴ1-Ⅴ16.
7Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn' s disease: current management. Gut, 2006, 55 (Suppl 1) : 16-35.
8Hanauer SB, Kane S. The pharmacology of antiminflammatory drugs in inflammatory bowel disease. In: Kirsner JB, ed. Inflammatory bowel disease. 5th ed. Philadelphia: W.B. Saunders Company, 2000, 510-528.
9Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut, 2005, 54:960-965.
10Cohen RD. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther, 2006, 24:465-474.
